BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD

Reuters03-04

BRIEF-<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD

March 4 (Reuters) - Clearmind Medicine Inc CMND.O:

CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF PHASE I/IIA CMND-100 TRIAL IN AUD

Source text: ID:nGNX4cf6yg

Further company coverage: CMND.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616530733?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616530733","market":"us","top_or_hot":-1,"title":"BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD</title></head><body><p><span>March 4 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine</a> Inc <span>CMND.O</span>:</p><ul><li><p>CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF PHASE I/IIA CMND-100 TRIAL IN AUD</p></li></ul><p>Source text: <span>ID:nGNX4cf6yg</span></p><p>Further company coverage: <span>CMND.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD</title></head><body><p><span>March 4 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine</a> Inc <span>CMND.O</span>:</p><ul><li><p>CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF PHASE I/IIA CMND-100 TRIAL IN AUD</p></li></ul><p>Source text: <span>ID:nGNX4cf6yg</span></p><p>Further company coverage: <span>CMND.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMND","symbol_name":"Clearmind Medicine, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1XJ:1","article_id":"2616530733","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616530733","pubTimestamp":1772628757,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUDMarch 4 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMND":"Clearmind Medicine, Inc.","BK4007":"制药"},"translate_title":"简介-Clearmind Medicine Inc-DSMB批准继续在澳大利亚进行I/Iia期Cmnd-100试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9},"content_text":"BRIEF-Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUDMarch 4 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - DSMB APPROVES CONTINUATION OF PHASE I/IIA CMND-100 TRIAL IN AUDSource text: ID:nGNX4cf6ygFurther company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616530733","isCrawlerRequest":true}